The country authorizes the marketing of the monkeypox vaccine

During the Council of Ministers of this Wednesday, August 3, an order was taken relating to the marketing of the vaccine against monkey pox. The epidemic continues to progress around the world. The European continent concentrates 70% of the cases of the epidemic in the world.


updated on August 3, 2022 at 4:34 p.m.

The Monkeypox virus or monkey pox currently gives rise to several epidemics around the world, and particularly in the United States and Europe. The European continent concentrates 70% of the cases of the epidemic in the world.


In order to anticipate the introduction of this virus in French Polynesia, the country has authorized the marketing of the vaccine against monkey pox, the specialty IMVANEX. Thus, French Polynesia authorizes the vaccine which would make it possible to vaccinate the population which would be identified at risk of being contaminated against smallpox. Procurement procedures are underway.

While the majority of cases of monkeypox are mild, ithe last few days have seen a chain of deaths, bringing to ten the number of deaths of people infected with monkeypox in the world since May. According to a count published by Public Health France on July 28, there were 1,955 cases of monkey pox in France. Worldwide, the number of monkeypox cases has risen to 18,000 since the beginning of May.

Most of the time, monkeypox heals itself after three weeks, with the appearance of scabs, which will cover the wounds that have appeared in patients. The best thing is still to protect yourself from the disease by getting vaccinated. In Metropolitan France, 42,000 doses have already been destocked in Ile-de-France, assured the Minister of Health, François Braun. 118 vaccination centers have been opened in France. Vaccination is done by injecting two doses of serum, 28 days apart.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.